Telmisartan Boosts Olaparib in 2 Cancer Trials as Blood Pressure Drug Widens PARP Reach
Updated
Updated · SciTechDaily · May 15
Telmisartan Boosts Olaparib in 2 Cancer Trials as Blood Pressure Drug Widens PARP Reach
1 articles · Updated · SciTechDaily · May 15
Dartmouth Cancer Center researchers reported that telmisartan, an FDA-approved hypertension drug, significantly increased olaparib’s tumor-killing effect and is already being tested in two early clinical trials.
Preclinical data showed the combination caused more DNA damage than olaparib alone and boosted type I interferon signaling, a key immune response the team says helps explain the stronger antitumor activity.
Telmisartan also appeared to extend PARP inhibitor sensitivity to tumors without the DNA-repair defects that usually predict response, potentially addressing a major limit of olaparib and related drugs.
Among angiotensin II receptor blockers tested, only telmisartan showed the effect; it also reduced tumor-cell PD-L1, suggesting broader potential alongside chemotherapy and immunotherapy.
The ongoing trials target metastatic castration-resistant prostate cancer and platinum-resistant ovarian cancer, with the prostate study’s first participant showing what the lead author called an exceptional response.
If telmisartan truly boosts olaparib’s power, what are the risks or unknowns as this combination moves from lab to real-world cancer care?
How close are we to repurposing everyday medications like telmisartan to revolutionize cancer treatment, and what hurdles remain before patients benefit?
Repurposed Hypertension Drug Telmisartan Dramatically Enhances PARP Inhibitor Efficacy in Early Cancer Trials (2026)
Overview
Recent breakthroughs in cancer treatment highlight the combination of telmisartan, a common blood pressure drug, with olaparib, a PARP inhibitor, as a promising new therapy. Preclinical studies show that this pairing increases the production of type I interferons, which help the immune system recognize and attack cancer cells. Telmisartan also lowers PD-L1 levels on tumor cells, making them less able to hide from immune defenses. These effects boost the immune response and reduce cancer’s ability to evade treatment, leading to early clinical trials that could expand effective options for a wider range of cancer patients.